% NKT Cell (CD56+ CD16+ T Cell)

Your immune system runs on specialists, but a small group of cells refuses to pick a side. These cells blend two jobs at once, acting like both a rapid-response killer and a targeted memory defender. Their share in your blood shifts measurably in cancer, chronic infection, and repeated pregnancy loss.

This is a research-stage measurement without agreed-upon normal cutpoints, so a single reading should not drive any decision on its own. What it can offer is an early, personal window into how your immune balance is changing over time.

What This Test Actually Measures

This test counts cells rather than measuring a substance like a hormone or protein. It uses a technique that sorts cells by the flags on their surface (called flow cytometry) to count what fraction of your immune cells are a hybrid type known as NKT-like cells (natural killer T-like cells).

These cells carry the identity tag of a classic T cell (a marker called CD3) alongside two flags normally seen on the immune system's fast-acting killers, called CD56 and CD16. That combination is what makes them a bridge between your body's quick, general defense and its slower, more precise one.

In healthy adults, the broader NKT-like population makes up roughly 5 to 15% of circulating T cells and less than 10% of circulating immune cells overall, and the CD16-positive slice is a subset within that. Their share also tends to rise with age. These cells are not the same as the rare, tightly defined invariant NKT cells, which is a common point of confusion.

Recurrent Pregnancy Loss and Fertility

The clearest test-performance data for this exact cell type come from reproductive medicine. In women with unexplained recurrent miscarriage, the double-positive CD3+CD56+CD16+ fraction ran higher than in women with a history of healthy pregnancy.

In one study, a cutoff of 2.55% flagged spontaneous abortion risk with 81.1% sensitivity and 98.8% specificity (a measure of how well a test separates two groups, where higher is better on both counts). A separate study of the same cell type landed on a different threshold of 3.75%, so the field has not settled on a single cutpoint. Another line of work found the opposite direction in repeated implantation failure, where a low share of a related peripheral killer-cell population (at or below 10.6%) tracked with lower pregnancy and implantation rates. That finding measured a related but different cell type (CD3-negative NK cells), so it is context, not direct evidence about this marker.

Colorectal Cancer

In colorectal cancer, findings on the total number of these hybrid cells are mixed. Some work focused on how the cells behave rather than their count, while at least one study found fewer of them in patients than in healthy donors. What appears to matter most is the CD16-positive slice within them, and here more is not better.

People with an above-average CD16-positive fraction faced roughly four times the risk of their cancer returning (hazard ratio 4.192, 95% CI 1.578 to 11.137), even after accounting for age, sex, and tumor stage. In these patients, the cells also showed signs of functional exhaustion, meaning they carried the killer flags but had lost some ability to actually attack, with lower CD16, raised inhibitory receptors, and weaker cytokine output.

Chronic Lymphocytic Leukemia

In chronic lymphocytic leukemia (a slow-growing blood cancer), the pattern flips. A lower share of these CD3+/CD16+CD56+ cells tracked with disease progression and a higher risk of death.

Patients with a lower fraction of these cells had shorter overall survival and needed treatment sooner than those with a higher fraction, a direction that held after accounting for other markers. This study measured the same cell type this test reports.

Severe Infections

In severe COVID-19, the percentage of these cells dropped alongside other immune populations, mirroring greater disease severity. In hospitalized COVID-19 patients, a related killer-cell proportion at or above 30% independently predicted in-hospital death (about twice the odds, OR 1.97).

In newly diagnosed HIV, lower CD16+CD56+ counts correlated with higher viral load, and a count below 73 cells per cubic millimeter flagged advanced disease with 95.5% sensitivity. Those HIV and COVID figures come from studies counting NK cells rather than the CD3-positive NKT-like cells specifically, so they describe a neighboring measurement, not this one directly.

Inflammatory and Autoimmune Conditions

The number can also climb in chronic immune irritation. In people with recurrent boils (recurrent furunculosis), both the number and percentage of CD3+CD16+CD56+ NKT-like cells were elevated.

In primary biliary cholangitis, an autoimmune liver disease, the percentage and absolute count of these cells were higher than in healthy controls. The direction here matches the inflammatory-activation pattern seen in some other immune-driven conditions.

Why High and Low Can Both Signal Trouble

It would be easy to read this as a contradiction, but it is not. This is not a simple high-is-bad or low-is-good number. It is a phenotype indicator, a snapshot of how activated and differentiated your immune killers are, and different immune states carry different risks. A rising cytotoxic-marker fraction in some cancers can reflect a compartment being driven toward exhaustion, while a falling number in leukemia or severe infection reflects an immune defense being depleted. The same value means different things depending on the clinical setting around it.

Why One Reading Is Not Enough

This marker carries high biological and technical variability, which is the single most important thing to know before acting on any result. Different labs define and gate these cells differently, and the number naturally shifts with age as your immune compartment matures. That means a lone value pulled from one draw is easy to misread.

Because there are no standardized cutpoints, the real value comes from watching your own trajectory. Get a baseline, retest in 3 to 6 months if you are tracking a health change, and then at least annually. Use the same lab each time, since results from different assays are not directly comparable.

What an Unexpected Result Should Prompt

An out-of-pattern number is a reason to look wider, not to act in isolation. The most useful next step is to interpret it against a fuller immune profile, including your CD4 and CD8 T cells, your B cells, and your standard NK cell counts, so you can see whether one compartment is shifting or the whole system is.

If the result is unexpected and paired with symptoms, a known cancer, a chronic infection, or fertility concerns, a hematologist or clinical immunologist is the right person to interpret it. Ask specifically whether your result is reported as a percentage or an absolute count, because those two framings can move in opposite directions and mean different things.

When Results Can Be Misleading

• Gating and definition: the biggest source of confusion is that labs define these cells differently. Some report CD3+CD56+, others CD3+CD16+CD56+, and the percentages are not interchangeable, so always match the exact definition when comparing results.
• Percentage versus count: a percentage can rise simply because other immune populations fell, not because these cells increased. In severe COVID-19, the killer-cell percentage climbed even as total lymphocytes dropped.
• Recent hard exercise: a single intense workout can roughly double the number of NKT-like cells in your blood within hours as they mobilize, then they leave circulation during recovery. This is temporary trafficking, so avoid testing right after strenuous exercise.
• Certain medications: drugs such as azathioprine and JAK inhibitors lower related cytotoxic killer-cell populations, which can shift a reading without reflecting your baseline immune state.